GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Celera Corporation (CRA) [hlAlert]

Rating:
Overweight
CRA
up 4.28 %

Celera Corporation (CRA) rated Overweight by Thomas Weisel

Posted on: Monday,  Mar 23, 2009  8:25 AM ET by Thomas Weisel

Thomas Weisel rated Overweight Celera Corporation (NASDAQ: CRA) on 03/23/2009, when the stock price was $7.71. Since
then, Celera Corporation has gained 4.28% as of 05/17/2011's recent price of $8.04.
If you would have followed this Thomas Weisel's recommendation on CRA, you would have gained 4.28% of your investment in 785 days.

Applera Corporation consists of two operating groups. Celera is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets.

At Thomas Weisel Partners, the role of Research is to contribute to our clients' decision process in ways that lead to better investment decisions. We cover the key growth sectors of the economy including Consumer, Energy, Financial Services, Healthcare, Internet, Media & Telecom, Metals & Mining and Technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/23/2009 8:25 AM Buy
None
7.71
as of 12/31/2009
1 Week down  -10.54 %
1 Month down  -2.08 %
3 Months down  -2.08 %
1 YTD down  -20.75 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy